No Data
No Data
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
Accuray's Precision Treatment Planning System Gains Approval in China
Lake Street Maintains Accuray(ARAY.US) With Buy Rating, Maintains Target Price $6
Lake Street analyst Brooks O'Neil maintains $Accuray(ARAY.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 44.5% and a total a
Accuray Precision TPS' Registration Dossier Approved in China
Express News | Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration
Accuray(ARAY.US) Officer Sells US$4,597.1 in Common Stock
$Accuray(ARAY.US)$ Officer Pervaiz Ali sold 2,701 shares of common stock on Jun 4, 2024 at an average price of $1.702 for a total value of $4,597.1.Source: Announcement What is statement of changes in
No Data